National Research Council of Canada

University of Alberta

Christine M Szymanski

Jamshid Tanha

Greg Hussack

Roger MacKenzie

Mehdi Arbabi Ghahroudi

Ali Riazi

Harald Nothaft

Mehdi Arbabi-Ghahroudi

Jean-Robert Brisson

Stephane Evoy

Noel M Young

Denis Arutyunov

Upasana Singh

John Francis Kelly

David C Watson

Harold C Jarrell

is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific tois described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VH) of a camelid animal immunized withflagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence ofin an animal or an animal environment, methods and formulations for treatinginfection, and method of detectingare also described.

Anti-campylobacter jejuni antibodies and uses therefor

The present application provides a vaccine composition comprising: bacteria engineered to express at least one N-glycan of, such asfor example, or an N-glycan derivative thereof on its cell surface; and one or more of a physiologically acceptable diluent, excipient, adjuvant or carrier. The bacteria isor any suitable bacteria that offers sufficient expression and improved immunogenic response. The vaccine composition can be formulated for administration to animals, such as poultry, including chickens.

Campylobacter vaccine

The invention provides isolated, purified, recombinant receptor binding proteins Gp-6, Gp-10 and Gp-31 fromphage L5, and methods for producing these recombinant receptor binding proteins. The invention also provides the use of recombinant receptor binding proteins, including Gp-6, Gp-10 and Gp-31, as probes for the identification and diagnosis ofinfections and conditions caused by. Further provided by the invention are methods of targeting mycobacteria using recombinant receptor binding proteins, including Gp-6, Gp-10 and Gp-31. Other methods provided by the invention include the use of recombinant receptor binding proteins, such as Gp-10, in diagnostic assays for diseases, such as Johne's disease, in animals, including ruminants.

Diagnosis and treatment of mycobacteria infections

An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by aorganism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by aorganism.

N-linked glycan compounds

Multiple strains and species of Campylobacter share a common glycan moiety which is present in a plurality of surface-exposed glycoproteins. This glycan has the formula: GalNAc-a1, 4-GalNAc-a1,4-[Glc-&#x3b2;1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2, 4-diacetamido-2,4,6-trideoxy-D-glucopyranose. This glycan and immunologically active fragments of it have use as vaccines against campylobacter infection in humans and animals. As well, antibodies which specifically bind these compounds may be provided. Such antibodies and vaccines may be used to prevent or neutralize campylobacter infections in livestock thereby preventing this pathogen from entering the human food chain. The glycan may be linked to one or more amino acids to form a glycopeptide. As well, a method for determining the glycan structure of an intact glycoprotein consists of subjecting a sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS-NMR) spectroscopy.

Campylobacter glycans and glycopeptides

Growing community of inventors

Ottawa, Canada

Christine M Szymanski